Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes aaaaaannnyyyyttthhing
Thursday, December 03, 2015
U.S. Stem Cell Reports Positive Results for Traumatic Brain Injury Patients
Stem cell research has seen significant interest from both, the scientific and investor community. However, stem cell research has also been a controversial area.
Writing in the GEN magazine, Lisa A. Haile, Phd, noted a few years ago that the stem cell field had made significant progress, which can be noticed from daily news reports on the research in the area globally.
Haile, however, noted that technical innovations, legal positions and regulatory challenges in one country or region could have implications for the regenerative medicine industry globally.
Stem cell industry is also highly controversial. Haile noted in her article that the Bush administration had placed restrictions on embryonic stem cell research. These restrictions were eventually lifted by the Obama administration. Indeed, under the Obama administration more funding is available for stem cell research.
The increased funding has enabled several biotech companies to focus on stem cell research.
This morning, one such company reported positive results for patients who have suffered traumatic brain injury (TBI).
Based in Sunrise, Florida, U.S. Stem Cell Inc. (OTCQB:USRM) is an emerging enterprise in the regenerative medicine/cellular therapy industry. The company is focused on the discovery, development and commercialization of cell-based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function.
Earlier today, USRM announced that it has successfully completed five physician based treatments of TBI patients. The company said that the five patients, who received stromal vascular fraction from adipose tissue delivered intrathecally, have been treated over the past 12 months at the U.S. Stem Cell Clinic, which is located in Sunrise, Florida.
The first patient treated by USRM has completed the 12-month folllowup and has far exceeded both the company’s and the patient’s own expectations. In addition, early progress is being tracked in four other patients. The company expects to provide detailed reports on them in the coming months.
Kristin Comella, Chief Scientific Officer at U.S. Stem Cell, said that the company is extremely encouraged by the positive patient results it is seeing from its physician-based treatments of TBI patients.
Comella further said that currently there are limited treatment options for patients who have suffered from TBI. Comella added that USRM’s hope is that stem cell therapy will provide relief and improved quality of life for TBI patients.
http://www.baystreet.ca/articles/stockstowatch.aspx?id=1115
Thursday, December 03, 2015
U.S. Stem Cell Reports Positive Results for Traumatic Brain Injury Patients
http://www.baystreet.ca/articles/stockstowatch.aspx?id=1115
Looking good here. News is inevitable. If you go to http://us-stemcell.com/products/myocell/ you can see that it has phase 3 Myocell "Underway"
Nice!!
While you were on the site I hope you checked out the other pages pertaining to:
USStemCellClinic.com
The work they do at that clinic is a large percentage of the revenues that are reported quarter over quarter.
While you're at it check out this site as it to belongs to US Stem Cell Inc and brings in revenues:
VetBiologics.com
Here they use a variety of cell therapies in order to heal animals and bring in revenues.
Do you think a medical staff of 6 is greater than the "4" people you assume work for US StemCell?
http://usstemcellclinic.com/medical-staff/
And do you think she also runs this website which is dedicated to the outpatient procedures they do??
Well then she must live here:
US StemCell inc.
13794 NW 4th Street
Suite 212
Sunrise, Florida 33325
Do you think she also maintains the website?
US-StemCell.com (Formally bioheartinc.com)
I wonder if she also files all the SEC documents that list the increased revenues quarter over quarter for over a year now.
Yes indeed. This is awesome, I expect big news to be honest. Why go through the hassle of RS, name change, website update etc... Revenues coming in and increasing. I'm invested to see a company succeed and to cash in when it does. I understand loses can occur before I invest. The big picture is they're business plan is moving forward and not at a stand still such as the stock has been and even in decline. The Business is moving FORWARD. IMO
Am I the only one who has read that a "Tender offer" is going to be made to buy up the retail shares around November 25th?
Yes I can, but I won't.
U.S. Stem Cell Inc looking good!!
And insider buying pre and post split?
http://ih.advfn.com/p.php?pid=nmona&article=69205976&xref=newsalert
http://ih.advfn.com/p.php?pid=nmona&article=69205981&xref=newsalert
U.S. Stem Cell, Inc. Reports Positive Results for 3Q 2015
[ACCESSWIRE]
SUNRISE, FL / ACCESSWIRE / November 6, 2015 / U.S. STEM CELL, Inc., a Florida corporation, (f/k/a/ Bioheart, Inc.) (PINKSHEETS: BHRTD) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to highlight the following results from operations for the quarter ending September 30, 2015:
- Current Liabilities (Debt) decreased 30.6% or $3.4 million, as of September 30, 2015 from $11.1 million to $7.7 million
- Working capital deficit improved 25% for the same time period year-over-year from $10 million (Q3 2014) to $7.5 million (Q3 2015)
- Revenue remained consistent and increased by 3.06% from $1,564,000 (Q3 2014) to $1,612,000 (Q3 2015)
- Expenses for the quarter decreased by 64.3% or over $1 million from $1.6 million (Q3 2014) to $564,000 (Q3 2015)
- Expenses as of September 30, 2015 decreased 31.5% (or over $1 million ) from approx. $3.3 million (YTD Q3 2014) to approx. $2.5 million (YTD Q3 2015)
"We are very pleased with our continuing quarter-over-quarter and year-over-year improvements in operations and balance sheet performance," stated Mike Tomas, President & CEO of U.S. Stem Cell Inc. "Moreover, we are making a real and positive impact on the lives of the patients we are treating. With our new brand in place and the completion of our reverse split, we continue to advance our key strategic business initiatives, which are to grow top line revenues, move the company to positive cash flows and to seek out new business opportunities for exponential growth. We thank our shareholders for the long-standing support and we look forward to reporting on our future successes."
About U.S. Stem Cell, Inc.
US Stem cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.
Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.
Have you read the most recent 10Q?
I wholeheartedly agree. GLTA
All of the above IMO
Sunrise, FL – October 2, 2015 – US STEM CELL, Inc., a Florida corporation, (in transition from Bioheart, Inc. (BHRT.OB)) a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to announce the completion of important transactions with ClearIt, LLC and Magna Equities II, LLC (“Magna”).
With ClearIt, LLC, the Company has secured the right to purchase up to a 15% non-consolidating membership stake in ClearIt and distribution rights to the ERASER™ System within the regenerative medicine industry. As previously announced, the ERASER™ system, if cleared by the US FDA (anticipated, but not guaranteed, for early 2017), we believe will be the first effective, painless, single treatment tattoo removal system that approaches 100% particle removal from the dermis while safely avoiding the side-effects of laser tattoo removal including scaring, skin color bleaching, shadow tattoos or absorption by the body of harmful minerals or chemical elements. ClearIt and US Stem Cell will also collaborate in the development of combination ERASER™/cell therapies for the treatment of acne, acne scars, psoriasis and certain skin cancer treatments.
With Magna, the Company has completed a $100,000 financing through a convertible note with a fixed conversion price. In connection with the execution of the convertible note, the Company and Magna also entered into a registration rights agreement whereby the Company has agreed to file an initial registration statement with the U.S. Securities & Exchange Commission. Details of this transaction are outlined in the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 2, 2015.
Company President and CEO, Mr. Mike Tomas, stated, “We are very pleased to be partnering with ClearIt in the development and future marketing of the ERASER™ System, which in the near and long-term will provide substantial value, revenues and profit to US Stem Cell, Inc. We are also pleased to continue our financial partnership with Magna who continues to believe in and support our strategic building plan. We also deeply appreciate our shareholder support in the actions we have and are taking to build US Stem Cell into a world class company."
Lol it's GREEN!!!
I strongly agree.
Excellent observation. Yes it does, and Ocata is moving forward nicely regardless of the current pps... I like our chances in the other conversation as well.
That's a healthy sum!!
Awesome!!
Company has been quite.... I like it.
Nice!
Investors can't invest if they don't know a company exists. Exposure is a huge part
Exposure.
That's a great read. It highlights our staff and technology.
"They" only shook the weak hands.
Ocata Therapeutics to Ring the NASDAQ Stock Market Opening Bell on June 24, 2015
http://ir.ocata.com/press-releases/detail/2783
Ocata Therapeutics Announces Pricing of $30 Million Offering of Common Stock and Warrants
http://ir.ocata.com/press-releases/detail/2782
We remain steadfast in our commitment to our doctors and their patients and to our shareholders and remain confident that our business strategy will continue to produce market and financial successes. We greatly appreciate your patience and look forward to updating you on our progress,
Sincerely,
William P. Murphy, Jr. M.D. Mike Tomas
Chairman
President and Chief Executive Officer
http://www.bioheartinc.com/assets/press/BioheartShareholderLetter-June32015_new.pdf
This is why I won't sell my shares. Things are in the works and it's only a matter of time before the stars align. IMO.
I won't be shaken either. Holding strong
Why can't you respect my OPINION and not disrespect me by claiming "BS"?
http://ih.advfn.com/p.php?pid=nmona&article=67025724&xref=newsalert
Priced at .0067 (purchased)
IMO they walked in with a suit case full of U.S. Currency and stated something to the extent of "I wanna buy X amount of shares at X amount price...CASH!"